Glaxosmithkline (LON:GSK) Hold Rating Reconfirmed by Analysts at Shore Capital; Telefonica Deutschland Holding AG (ETR:O2D) Had 7 Bulls

November 23, 2017 - By wolcottdaily

Among 13 analysts covering O2 (ETR:O2D), 7 have Buy rating, 2 Sell and 4 Hold. Therefore 54% are positive. O2 had 32 analyst reports since June 23, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Saturday, January 16 by Bankhaus Lampe. The rating was upgraded by Commerzbank on Thursday, October 22 to “Add”. The stock has “Hold” rating by Bankhaus Lampe on Tuesday, September 1. The firm earned “Hold” rating on Friday, October 30 by Warburg Research. HSBC upgraded Telefonica Deutschland Holding AG (ETR:O2D) on Thursday, December 3 to “Buy” rating. The stock of Telefonica Deutschland Holding AG (ETR:O2D) has “Buy” rating given on Wednesday, October 21 by UBS. The stock has “Buy” rating by Berenberg on Tuesday, January 5. Berenberg upgraded Telefonica Deutschland Holding AG (ETR:O2D) on Tuesday, November 10 to “Buy” rating. Citigroup upgraded Telefonica Deutschland Holding AG (ETR:O2D) on Thursday, September 10 to “Buy” rating. Deutsche Bank maintained Telefonica Deutschland Holding AG (ETR:O2D) on Thursday, September 17 with “Hold” rating. See Telefonica Deutschland Holding AG (ETR:O2D) latest ratings:

Today, Shore Capital kept their Hold rating on Glaxosmithkline (LON:GSK)‘s stock in a note issued.

Telefonica Deutschland Holding AG is a Germany firm engaged in the telecommunication industry. The company has market cap of 12.00 billion EUR. The Firm offers mobile and fixed-line services providing voice, data and other services to retail and business customers. It currently has negative earnings. It also acts as a wholesale provider, offering access to its infrastructure and service capabilities to its wholesale partners.

The stock decreased 1.18% or EUR 0.05 on November 23, reaching EUR 4.03. About 3.82M shares traded or 44.70% up from the average. Telefonica Deutschland Holding AG (ETR:O2D) has 0.00% since November 23, 2016 and is . It has underperformed by 16.70% the S&P500.

GlaxoSmithKline plc is a global healthcare company. The company has market cap of 64.22 billion GBP. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 27.48 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

The stock increased 0.24% or GBX 3.16 on November 23, reaching GBX 1305.66. About 7.31M shares traded. GlaxoSmithKline plc (LON:GSK) has 0.00% since November 23, 2016 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>